Tamoxifen (TMX), sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men.[1] It is also being studied for other types of cancer[1]. Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER)-positive (ER+) breast cancer in pre- and post-menopausal women[2]. Additionally, it is the most common hormone treatment for male breast cancer. [1]: https://www.cancer.gov/about-cancer/treatment/drugs/tamoxifencitrate [2]: Jordan, V. Craig. "A current view of tamoxifen for the treatment and prevention of breast cancer." British journal of pharmacology 110.2 (1993): 507-517. f3d fe9 fe6 c03 a43 16480962 PubMed Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 2006 Ogura K Ishikawa Y Kaku T Nishiyama T Ohnuma T Muro K Hiratsuka A 17186017 PubMed Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007 Jordan VC xenobiotic metabolic pathway PW:0001229 Pathway Ontology breast cancer pathway PW:0000624 Pathway Ontology 17765940 PubMed New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007 Jordan VC 19250197 PubMed Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 2009 Lazarus P Blevins-Primeau AS Zheng Y Sun D 15135306 PubMed Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 2004 Kaku T Ogura K Nishiyama T Ohnuma T Muro K Hiratsuka A estrogen-receptor positive breast cancer DOID:0060075 Disease